Access cutting-edge liver cancer treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access liver cancer specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related liver cancer treatment provided free
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy Cohorts (Cohort 2 and 3) Cohort 2 (HCC) This part is a single-agent, single one-dose level and single-arm design. Approximately 39 subjects will be enrolled in the study to receive VG161. In the first stage, 21 subjects will be enrolled. If there is only 1 or fewer subjects has been observed with objective response and no more than 12 (\<13
Sponsor: Virogin Biotech Canada Ltd
Check if you qualify for this liver cancer clinical trial in Phoenix, AZ
If you're searching for liver cancer treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced liver cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.